Trial Profile
A Phase I, Open Label, Safety Study of INXN-4001 Delivered Via Retrograde Coronary Sinus Infusion in Patients With an Outpatient Left Ventricular Assist Device (LVAD)
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 09 Mar 2021
Price :
$35
*
At a glance
- Drugs INXN 4001 (Primary)
- Indications Heart failure
- Focus Adverse reactions; First in man
- Sponsors Triple-Gene
- 01 Mar 2021 According to a Precigen media release, Interim data at 12-Month Follow-up announced in January 2021.
- 03 Dec 2020 Status changed from active, no longer recruiting to completed.
- 06 Aug 2020 According to a Precigen media release, the company looks forward to sharing the final study results at the 12-month interval.